A New Biotech Deal, a Buyout Premium, and Another Push Into Custom AI Chips

One healthcare giant is still spending to deepen its pipeline, one building-products name just turned into a merger-spread story overnight, and one semiconductor winner is picking up another custom-chip tailwind. The setups are all live, but the right move depends on whether you want steady compounding, deal risk, or AI exposure bought on weakness.

No one believed Whitney Tilson when he predicted the collapse of Bear Stearns and Lehman Brothers. Or when he went on 60 Minutes exposing a company poisoning its own customers. (The stock fell nearly 80%.)

Now he has a new warning about what's REALLY around the corner for America's most beloved tech companies.

Watch for free here.

Futures are pulling back as U.S.-Iran tensions heat up again and oil jumps on fresh shipping fears in the Gulf. After a huge run to new highs, the market looks like it is finally taking a breath as traders reset for another round of geopolitical whiplash.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• Cleveland-Cliffs Inc. [CLF]
• Bank of Hawaii Corporation [BOH]
• Dynex Capital, Inc. [DX]

Earnings (Aftermarket):
• Steel Dynamics, Inc. [STLD]
• AGNC Investment Corp. [AGNC]
• Wintrust Financial Corporation [WTFC]
• Zions Bancorporation N.A. [ZION]
• BOK Financial Corporation [BOKF]
• Alaska Air Group, Inc. [ALK]
• ServisFirst Bancshares, Inc. [SFBS]

Economic Reports:
• None scheduled

That difference matters more than the raw dollar amount.

Grab insiders sold just under $394,000 across the CFO and Chief Product Officer, while Trimble executives logged a wave of option exercises and only one actual open-market sale of about $1.12 million. That distinction is the story. One filing set points to modest profit-taking. The other looks more like a compensation-related activity with limited urgency to dump stock.

This is just the tip of the iceberg when it comes to ways to profit from inside activity, and you’re missing the full story.

Every day, insiders and institutions move millions before the market catches on. Elite Trade Club Insider gives you the data they don’t want you to see.

A subscription gets you:

Eli Lilly and Co. (NYSE: LLY) is reportedly in advanced talks to buy Kelonia Therapeutics for more than $2 billion, with additional milestone payments possible if the deal closes. Kelonia is a clinical-stage biotech focused on genetic medicines and CAR-T therapies, so this looks like another step in Lilly’s broader push to build out beyond obesity and diabetes.

That matters because Lilly has been using its weight-loss cash machine to widen the moat in other high-value areas. Oncology already includes assets like Jaypirca and Verzenio, and a Kelonia deal would deepen Lilly’s position in a part of biotech where competition is intense but the upside can be very large if the science works.

The company also said in February it would acquire Orna Therapeutics for up to $2.4 billion, so this is not a one-off move.

LLY closed at $927.03, up 13.3% over the past year, and still trades below its 52-week high of $1,133.95. That leaves room for the market to reward smart pipeline expansion, but investors will still want to know how much of this acquisition is near-term value versus long-cycle promise.

My Take For You: Lilly is acting like a company that wants to stay a growth leader after the obesity boom matures. That is a plus, but pipeline deals need time before they show up in numbers.

My Verdict: Buy on pullbacks if you want large-cap healthcare exposure with real expansion optionality. The risk is that expensive biotech deals add promise faster than they add earnings.

TopBuild Corp (NYSE: BLD) surged after QXO offered to acquire the company in a cash-and-stock deal valuing TopBuild at about $17 billion. The offer values BLD at $505 per share, which is roughly a 23% premium to the prior close and instantly changes how investors need to think about the stock.

This is not just a generic consolidation story. QXO says the deal would make it the second-largest publicly traded building products distributor in North America, with more than $18 billion in combined revenue and over $2 billion in adjusted EBITDA.

It also gives QXO greater exposure to large, complex projects such as data centers, where insulation and building systems demand should stay firm as AI infrastructure expands.

BLD closed at $410.31 before the new session, so the stock still sits below the headline offer price. That creates a classic merger-spread setup where the market is weighing completion risk, timing, and the odds of anything changing before an expected third-quarter 2026 close. If the deal holds together, the spread narrows. If something breaks, the stock can give back a lot of the pop.

My Take For You: This is now more of a deal trade than a pure operating story. The upside is tied to deal certainty, not just business momentum.

My Verdict: Buy only if you are comfortable playing the merger spread into closing. The risk is that deal terms change or the transaction stalls, and the stock drops back toward stand-alone value.

Until you've heard this urgent AI warning from the man who called Nvidia before its 44,000% rise… According to Louis, a massive reset is coming in an obscure corner of the AI market.

This $100 trillion disruption could send some of the world's biggest AI stocks to zero… and one off-the-radar stock soaring… starting now.

Click here for details and Louis' new pick — free.

*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

Marvell Technology Inc. (NASDAQ: MRVL) is back in focus after reports that Google is in talks with the company on next-generation custom AI chips. The reported work includes a memory processing chip and a new TPU design, both aimed at improving efficiency and reducing reliance on Nvidia-style general-purpose GPUs for AI workloads.

That matters because the custom silicon race is getting more serious. Hyperscalers want lower costs, tighter performance, and more control over their own AI infrastructure, and Marvell has positioned itself as one of the more important partners in that shift.

A deeper relationship with Google would also diversify Marvell’s customer base while reinforcing its role across custom compute, connectivity, and optical infrastructure for AI data centers.

MRVL closed at $139.69 and was up another 5.4% premarket, pushing toward a fresh high after already gaining 182.9% over the past year. The stock has earned a premium because investors see Marvell as one of the cleanest ways to play the custom-chip buildout. The challenge is that some of the upside is already in the price, and the reported timeline for one of the chips stretches out toward 2027.

My Take For You: The custom AI chip story keeps getting stronger, and Marvell remains close to the center of it. This is a real trend, but the stock now needs continued deal flow and execution to justify the valuation.

My Verdict: Buy on pullbacks while hyperscaler custom-chip spending keeps rising. The risk is that a rich valuation leaves little room for delays or softer demand.

Sable is bouncing again as traders keep leaning into the recovery story. The stock still has bulls pointing to analyst upside, including a $30 target from Jefferies versus a broader consensus around $19.50, and the shares are trading well above both the 50-day and 200-day moving averages.

But the stock also comes with baggage. Insiders sold about 837,000 shares worth nearly $14 million last quarter, and this remains a company losing money with the market split between Buy and Sell calls.

ASTS is getting hit because the market is finally pushing back on the valuation. The long-term story still sounds huge, but the near-term setup is brutal: big capital needs, delayed timelines, modest revenue in the years right ahead, and real dilution risk if funding has to be raised again.

This stock is still up more than 300% over the past year, so there is plenty of air under it when sentiment turns. Scotiabank flagging downside risk is enough to shake out a name that already trades on future dreams more than present numbers.

Mirum is slipping after a director sold 2,000 shares for about $193,800, but this does not look like a serious crack in the story. The sale was done under a 10b5-1 plan, analysts are still sitting on targets like $125, $132, and $140, and 2026 still has multiple trial readouts and potential label-expansion catalysts ahead.

Yes, the stock has had a huge run and may be rich in the short term. But one small planned insider sale does not outweigh a pipeline with this many meaningful shots on goal.

Americans are discovering a rare "29% Account" that pays 72X more than what your bank offers.

It's NEVER been advertised to the general public… the big banks and financial giants have kept it to themselves for decades.

Now it's available to everyday Americans - and banks are NOT happy about it.

Discover the "29% Account" here before they try to ban it.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.